UNDIFFERENTIATED PLEOMORPHIC SARCOMA, INFLAMMATORY VARIANT

Clinical trials for UNDIFFERENTIATED PLEOMORPHIC SARCOMA, INFLAMMATORY VARIANT explained in plain language.

Never miss a new study

Get alerted when new UNDIFFERENTIATED PLEOMORPHIC SARCOMA, INFLAMMATORY VARIANT trials appear

Sign up with your email to follow new studies for UNDIFFERENTIATED PLEOMORPHIC SARCOMA, INFLAMMATORY VARIANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New Two-Pronged attack tested against rare cancers before surgery

Disease control Ongoing

This early-stage study is testing the safety of combining two immunotherapy drugs, nivolumab and BO-112, given before surgery for patients with operable soft tissue sarcoma. The goal is to see if stimulating the immune system to attack the tumor before it is removed can improve o…

Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA, INFLAMMATORY VARIANT

Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control

Last updated Mar 24, 2026 12:02 UTC

UNDIFFERENTIATED PLEOMORPHIC SARCOMA, INFLAMMATORY VARIANT

Get alerted when new UNDIFFERENTIATED PLEOMORPHIC SARCOMA, INFLAMMATORY VARIANT trials appear

New Two-Pronged attack tested against rare cancers before surgery